You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 12, 2024

EDARAVONE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for edaravone and what is the scope of patent protection?

Edaravone is the generic ingredient in three branded drugs marketed by Dr Reddys, Gland Pharma Ltd, Hikma, Long Grove Pharms, and Mitsubishi Tanabe, and is included in six NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Edaravone has twenty-one patent family members in fourteen countries.

Four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for EDARAVONE
Recent Clinical Trials for EDARAVONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Simcere Pharmaceutical Co., LtdPhase 3
Xiangya Hospital of Central South UniversityPhase 3
First Affiliated Hospital of Guangxi Medical UniversityN/A

See all EDARAVONE clinical trials

Generic filers with tentative approvals for EDARAVONE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up30MG/100ML(0.3MG/ML)INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for EDARAVONE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RADICAVA ORS Oral Suspension edaravone 105 mg/5 mL 215446 1 2023-04-20

US Patents and Regulatory Information for EDARAVONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mitsubishi Tanabe RADICAVA ORS edaravone SUSPENSION;ORAL 215446-001 May 12, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for EDARAVONE

Country Patent Number Title Estimated Expiration
Mexico 2024000663 SUSPENSION DE EDARAVONA PARA ADMINISTRACION ORAL. (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION.) ⤷  Sign Up
European Patent Office 3875085 SUSPENSION D'ÉDARAVONE DESTINÉE À ÊTRE ADMINISTRÉE PAR VOIE ORALE (EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION) ⤷  Sign Up
Denmark 3875085 ⤷  Sign Up
China 117398346 用于口服给药的依达拉奉混悬剂 (Edaravone suspension for oral administration) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.